NEW DELHI: Drug major Glenmark Pharma on Tuesday said it has received tentative approval from the US health regulator for Axitinib tablets, used in the treatment of kidney cancer.The tentatively approved product is the generic version of Inlyta tablets of PF Prism CV.Glenmark Pharmaceuticals Inc, USA has received tentative approval by the United States Food & Drug Administration (USFDA) for Axitinib tablets in the strength of 1 mg and 5 mg, the company said in a regulatory filing.Quoting IQVIA sales data for the 12 months ending October 2020, Glenmark Pharma said the Inlyta Tablets, 1 mg and 5 mg market achieved annual sales of approximately USD 518.8 million.Glenmark's current portfolio consists of 166 products authorised for distribution in the US market and 45 ANDA's pending approval with the USFDA.
Monday, November 30, 2020
Home
Economic News
Glenmark Pharma gets tentative nod from USFDA for cancer treatment drug | Economic Times
Glenmark Pharma gets tentative nod from USFDA for cancer treatment drug | Economic Times
Subscribe to:
Post Comments (Atom)
-
HYDERABAD: The National Institute of Nutrition (NIN) has added another 5kg to the ideal weight of Indians. While the weight of an ideal or r...
-
Morgan Stanley and JPMorgan say buy the dip after treasury rout https://ift.tt/VBYjxPd Stanley sees scope for a rebound in Treasuries on exp...
-
Maruti an attractive bet on high margins, but slowing demand could be a worry https://ift.tt/VrpMTAI course, we aren't talking about its...
No comments:
Post a Comment